TRIB2 and esophageal squamous cell carcinoma: MiR-99a-5p blocks CSC persistence and sensitizes ESCC cells to radiotherapy by first targeting TRIB2 and blocking HDAC2 activation via the mTOR signaling pathway (Liu et al., 2021b; Sun et al., 2013).